A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2 Mutated, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 24 Jul 2024
At a glance
- Drugs BL-M07D1 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 11 May 2024 Planned End Date changed from 1 Mar 2026 to 1 Apr 2026.
- 11 May 2024 Planned primary completion date changed from 1 Mar 2026 to 1 Apr 2026.
- 11 May 2024 Status changed from not yet recruiting to recruiting.